您的位置: 首页 > 农业专利 > 详情页

METHOD OF TREATMENT OF CENTRAL CORNEAL ULCERS OF BACTERIAL AND HERPETIC ETIOLOGY
专利权人:
Federalnoe gosudarstvennoe byudzhetnoe uchrezhdenie "Moskovskij nauchno-issledovatelskij institut glaznykh boleznej imeni Gelmgoltsa" Ministerstva zdravookhraneniya Rossijskoj Federatsii
发明人:
Neroev Vladimir Vladimirovich (RU),Нероев Владимир Владимирович (RU),Katargina Lyudmila Anatolevna (RU),Катаргина Людмила Анатольевна (RU),Kovaleva Lyudmila Anatolevna (RU),Ковалева Людмила Анатольевн
申请号:
RU2018109430
公开号:
RU0002668713C1
申请日:
2018.03.16
申请国别(地区):
RU
年份:
2018
代理人:
摘要:
FIELD: medicine.SUBSTANCE: invention relates to ophthalmology and is intended for the treatment of central corneal ulcers of bacterial and herpetic etiology. Carry out therapeutic treatment with etiotropic means, drugs that stimulate epithelization. Sensitization to antigens of the cornea is determined. If it is available, additionally, dexamethasone is injected parabulbarly every day, until the epithelialization of the ulcer and the resorption of the corneal infiltrate are completed. At a depth of ulceration up to 1/3 of the thickness of the stroma of the cornea, 1.2 mg of dexamethasone is injected in a volume of 0.3 ml. At a depth of ulceration up to 1/3–2/3 of the thickness of the stroma of the cornea, 0.8 mg of dexamethasone is injected in a volume of 0.2 ml. At a depth of ulceration up to 2/3 of the thickness of the stroma of the cornea, 0.4 mg of dexamethasone is injected in a volume of 0.1 ml.EFFECT: method provides prevention of destruction of all layers of the cornea, reduction of edema and infiltration of the cornea, a reduction in uveitis in the first day after the start of treatment, early resorption of the infiltrate and epithelization of the corneal ulcer in a short time, prevention of corneal perforation, preservation and restoration of visual functions due to the use of a certain regimen of parabulbar injection of dexamethasone depending on the depth of stromal lesion in the corneal ulcer in the presence of autosensitization to corneal antigens.4 cl, 6 exИзобретение относится к офтальмологии и предназначено для лечения центральных язв роговицы бактериальной и герпетической этиологии. Проводят терапевтическое лечение с помощью этиотропного средства, препаратов, стимулирующих эпителизацию. Определяют сенсибилизацию к антигенам роговицы. При ее наличии дополнительно ежедневно один раз в сутки парабульбарно вводят дексаметазон до завершения эпителизации язвы и резорбции инфильтрата роговицы. При глубине изъязвления до 1/3 толщины стромы роговицы вводят п
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充